PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
RYR significantly reduces total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) [PMID:36259545, PMID:38794691]. LDL-C reductions are reported between 15% and 34% compared to placebo [PMID:31687098, PMID:31643497, PMID:40881894].
RYR is associated with improvements in endothelial function and arterial stiffness [PMID:31687098, PMID:33538260]. One large RCT in China found it significantly improved the risk of major adverse cardiovascular events and overall survival following myocardial infarction [PMID:24003656].
A systematic review of 10 RCTs found no statistically significant difference between RYR and simvastatin in outcomes for total cholesterol, LDL-C, HDL-C, and triglycerides [PMID:26956355].
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 31687098 (2019) — Red Yeast Rice for Hypercholesterolemia. · Methodist DeBakey cardiovascular journal
- 2.PMID: 33538260 (2021) — Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. · Journal of the American College of Cardiology
- 3.PMID: 31643497 (2012) — Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review. · Nutrients
- 4.PMID: 36259545 (2023) — Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials. · Expert review of clinical pharmacology
- 5.PMID: 38794691 (2024) — Safety and Efficacy of the Consumption of the Nutraceutical "Red Yeast Rice Extract" for the Reduction of Hypercholesterolemia in Humans: A Systematic Review and Meta-Analysis.